Page last updated: 2024-09-02

ecteinascidin 743 and Allergy, Drug

ecteinascidin 743 has been researched along with Allergy, Drug in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Colombo, N; Ferrandina, G; Hardy-Bessard, AC; Marth, C; Romero, I	1

Reviews

1 review(s) available for ecteinascidin 743 and Allergy, Drug

Article	Year
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge. Expert review of anticancer therapy, 2016, Volume: 16, Issue:sup1 Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Hypersensitivity; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome	2016

Article

Year

Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.

Expert review of anticancer therapy, 2016, Volume: 16, Issue:sup1

Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Hypersensitivity; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2016